MDR Rule 18: Tissue-Derived Devices Default to Class III

Manufacturers carrying over the animal-tissue mental model from the old Medical Devices Directive regime routinely under-classify devices built from human-derived material. Annex VIII's Rule 18 puts devices manufactured using non-viable human or animal tissues, cells, or their derivatives in Class III by default — and its one stated exception, for devices intended for contact with intact skin only, was written for animal-origin material specifically. It has never reached human-origin devices, no matter how superficial their intended use looks on paper.

The default is Class III, and the scope is wide

Rule 18's trigger language — "manufactured utilising" tissues, cells, or their derivatives — reaches further than the finished product's obvious source material. It covers devices built from processed derivatives like collagen, gelatin, or decellularized matrices, not just products that look like transplant or graft material on their face. Once a device is confirmed to be manufactured using non-viable human or animal tissue, cells, or a derivative of either, Rule 18 puts it in Class III as the starting position, the same outcome Rule 14's ancillary-substance test reaches for devices with an integral medicinal substance — a high-consequence class with a narrow, specifically worded way out.

The intact-skin exception has a narrower reach than it looks

The exception reads simply: devices of animal origin, non-viable or rendered non-viable, intended for contact with intact skin only, are Class I instead of Class III. Teams that learned device-tissue classification under the earlier animal-tissue-only Directive regime sometimes extend that carve-out by instinct to any tissue-derived device with a superficial, non-invasive use — a reasonable-sounding read that is simply wrong under MDR. The exception's text is origin-specific, not use-specific: it applies because the material is animal-derived, not because the device only touches intact skin. A human-derived collagen dressing intended for the same intact-skin use gets no such exception and defaults to Class III.

• Animal-derived collagen dressing, intact skin only. Qualifies for the exception — Class I, provided the device genuinely limits itself to intact-skin contact.
• Animal-derived collagen matrix, implantable or internal use. No exception applies; Class III, both because the material is covered by Rule 18 and because invasive use removes any basis for the intact-skin carve-out regardless.
• Human-derived collagen or acellular dermal matrix product, even for intact-skin use. Class III. The intact-skin exception does not exist for human-origin material under Rule 18, regardless of how limited the intended contact is.
• Genuinely raw, unprocessed non-viable tissue or cells. May fall outside MDR scope entirely under Article 1(6), governed instead by the tissue establishment rules in Directive 2004/23/EC — a scope question that has to be settled before Rule 18 is even reached.

Rule 18's exception was written for animal tissue in intact-skin devices. It was never written for human tissue, no matter how superficial the device's use. Where the old animal-tissue mental model stops applying

Classification and scope are two different questions

Rule 18 is the downstream classification question; whether the product is a device at all is the upstream one, and the two get run together more often than they should. A tissue establishment processing non-viable human tissue for direct clinical application, with no further device manufacturing step, is typically working under Directive 2004/23/EC's tissue-and-cell framework rather than the MDR. The moment that material is manufactured into a finished product — extracted, processed, and built into something placed on the market as a device — the MDR applies and Rule 18's classification question starts. Teams that settle the MDCG 2022-5 borderline mode-of-action test for device-versus-other-product-category status, then separately and explicitly work the Rule 18 origin-and-exception analysis, avoid discovering either gap only when a notified body's file review raises it.

The practical risk runs in both directions. Classifying a human-origin tissue-derived device as Class I by misapplying the animal-only exception invites a notified body correction mid-review, with a Class III conformity assessment route added to the critical path late. Assuming every tissue-adjacent product needs the full Rule 18 analysis, without first settling whether it is manufactured material in MDR scope at all, risks routing a genuinely tissue-establishment product through device conformity assessment it was never meant to need. Our tissue-engineered products and biomaterials classification teams run both questions at the design stage, so the Rule 18 call is settled before a notified body's own read of it becomes the first time anyone asked.